glp-1 drugs and cancer GLP-1s appear to cut risk. Researchers are asking why how : NPR The effect of GLP-1R agonists

Third-party testing means an external, accredited laboratory with no financial stake in the product performs the analysis

The Journal of Law and Economics

doi: 10.2174/1871527322666230303114425

Despite competition from long-acting alternatives, nearly 36% market share indicates steady demand supported by specific patient needs and clinical outcomes

In that role, they help the body manage blood sugar more effectively, slow digestion, and increase satiety, which can lead to decreased appetite and food intake

In the most directly relevant comparator with semaglutide, MASH resolution was achieved in 62.9% of patients on the drug while fibrosis improvement reached only 36.8%, leaving substantially less overlap than the headline numbers might imply [16]